Comparison between Emcure Pharmaceuticals IPO and Stanley Lifestyles IPO.
Emcure Pharmaceuticals IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Stanley Lifestyles IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Emcure Pharmaceuticals IPO is up to ₹1,952.03 Cr whereas the issue size of the Stanley Lifestyles IPO is up to ₹537.02 Cr. The final issue price of Emcure Pharmaceuticals IPO is ₹1,008.00 per share and of Stanley Lifestyles IPO is ₹369.00 per share.
| Emcure Pharmaceuticals IPO | Stanley Lifestyles IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹2 per share |
| Issue Price (Lower) | ₹960.00 per share | ₹351.00 per share |
| Issue Price (Upper) | ₹1,008.00 per share | ₹369.00 per share |
| Issue Price (Final) | ₹1,008.00 per share | ₹369.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹90.00 per share | |
| Market Lot Size | 14 shares | 40 shares |
| Fresh Issue Size | 79,46,231 shares | 54,20,054 shares |
| Fresh Issue Size (Amount) | up to ₹800.58 Cr | up to ₹200.00 Cr |
| OFS Issue Size | 1,14,28,839 shares | 91,33,454 shares |
| OFS Issue Size (Amount) | up to ₹1,151.45 Cr | up to ₹337.02 Cr |
| Issue Size Total | 1,93,75,070 shares | 1,45,53,508 shares |
| Issue Size Total (Amount) | up to ₹1,952.03 Cr | up to ₹537.02 Cr |
Emcure Pharmaceuticals IPO opens on Jul 03, 2024, while Stanley Lifestyles IPO opens on Jun 21, 2024. The closing date of Emcure Pharmaceuticals IPO and Stanley Lifestyles IPO is Jul 05, 2024, and Jun 25, 2024, respectively.
| Emcure Pharmaceuticals IPO | Stanley Lifestyles IPO | |
|---|---|---|
| Anchor Bid Date | Jul 02, 2024 | Jun 20, 2024 |
| Issue Open | Jul 03, 2024 | Jun 21, 2024 |
| Issue Close | Jul 05, 2024 | Jun 25, 2024 |
| Basis Of Allotment (Tentative) | Jul 08, 2024 | Jun 26, 2024 |
| Initiation of Refunds (Tentative) | Jul 09, 2024 | Jun 27, 2024 |
| Credit of Share (Tentative) | Jul 09, 2024 | Jun 27, 2024 |
| Listing date (Tentative) | Jul 10, 2024 | Jun 28, 2024 |
| Anchor Lockin End date 1 | Aug 07, 2024 | Jul 26, 2024 |
| Anchor Lockin End date 2 | Oct 06, 2024 | Sep 24, 2024 |
Emcure Pharmaceuticals IPO P/E ratio is 34.55, as compared to Stanley Lifestyles IPO P/E ratio of 54.43.
| Emcure Pharmaceuticals IPO | Stanley Lifestyles IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 83.21 | 67.36 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 78.08 | 56.81 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 34.55 | 54.43 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹19029.89 Cr. | ₹2103.94 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 16.90% | 7.92% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 19.37% | 8.63% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.67 | 0.86 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹29.17 | ₹6.78 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 16.87% | 8.34% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Emcure Pharmaceuticals IPO Retail Individual Investors (RII) are offered 67,43,160 shares while in Stanley Lifestyles IPO retail investors are offered 67,43,160 shares. Qualified Institutional Buyers (QIB) are offered 38,53,234 shares in Emcure Pharmaceuticals IPO and 29,10,702 shares in Stanley Lifestyles IPO.
| Emcure Pharmaceuticals IPO | Stanley Lifestyles IPO | |
|---|---|---|
| Anchor Investor Reservation | 57,79,850 shares | 43,66,051 shares |
| Market Maker Reservation | ||
| QIB | 38,53,234 shares | 29,10,702 shares |
| NII | 28,89,926 shares | 21,83,027 shares |
| RII | 67,43,160 shares | 50,93,728 shares |
| Employee | 1,08,900 shares | |
| Others | ||
| Total | 1,93,75,070 shares | 1,45,53,508 shares |
Emcure Pharmaceuticals IPO subscribed 67.87x in total, whereas Stanley Lifestyles IPO subscribed 97.16x.
| Emcure Pharmaceuticals IPO | Stanley Lifestyles IPO | |
|---|---|---|
| QIB (times) | 191.24x | 215.62x |
| NII (times) | 49.32x | 121.42x |
| Big NII (times) | 54.90x | 136.75x |
| Small NII (times) | 38.16x | 90.76x |
| RII (times) | 7.36x | 19.08x |
| Employee (times) | 8.81x | |
| Other (times) | ||
| Total (times) | 67.87x | 97.16x |
